Description: CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally.
Home Page: www.cvrx.com
CVRX Technical Analysis
9201 West Broadway Avenue
Minneapolis,
MN
55445
United States
Phone:
763 416 2840
Officers
| Name | Title |
|---|---|
| Mr. Nadim Yared | CEO, Pres & Director |
| Mr. Jared Oasheim | Chief Financial Officer |
| Mr. Paul Verrastro | Chief Marketing & Strategy Officer |
| Mr. Paul Pignato | VP of Operations |
| Mr. Craig Palmer | Sr. VP of US Sales |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.2414 |
| Price-to-Book MRQ: | 2.4006 |
| Price-to-Sales TTM: | 16.2167 |
| IPO Date: | 2021-06-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 109 |